Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 16/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | KIT | P10721 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2516635 | 1.00 | IDO1 (0.60) | IDO1POLBHPGDLMNAMAPT | |
| SCHEMBL6046663 | 0.85 | NPC1 (0.46) | IDO1POLBHPGDLMNAMAPT | |
| SCHEMBL6046661 | 0.85 | NPC1 (0.46) | IDO1POLBHPGDLMNAMAPT | |
| SCHEMBL2521461 | 0.85 | POLB (0.61) | IDO1POLBHPGDLMNAMAPT | |
| SCHEMBL2521464 | 0.85 | POLB (0.61) | IDO1POLBHPGDLMNAMAPT | |
| SCHEMBL2516712 | 0.84 | IDO1 (0.58) | IDO1LMNAMAPTKITKDR | |
| SCHEMBL18845664 | 0.84 | IDO1 (0.58) | IDO1LMNAMAPTBCHEKIT | |
| SCHEMBL2520566 | 0.84 | IDO1 (0.58) | IDO1LMNAMAPTKITKDR | |
| SCHEMBL2520561 | 0.84 | IDO1 (0.58) | IDO1LMNAMAPTKITKDR | |
| SCHEMBL2513774 | 0.84 | IDO1 (0.58) | IDO1LMNAMAPTBCHEKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3085697-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME | Incyte Holdings Corporation (US) | 2016-10-26 | — | — | EP | claimed |
| US-20130123246-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME | INCYTE CORPORATION (US) | 2013-05-16 | — | — | US | claimed |
| US-20110311479-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME | INCYTE CORPORATION, A DELAWARE CORPORATION | 2011-12-22 | — | — | US | claimed |
| US-20060258719-A1 | Modulators of indoleamine 2,3-dioxygenase and methods of using the same | INCYTE CORPORATION | 2006-11-16 | — | — | US | claimed |
| US-11192868-B2 | Modulators of indoleamine 2,3-dioxygenase and methods of using the same | INCYTE CORPORATION (US) | 2021-12-07 | — | — | US | disclosed |
| US-20190210985-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME | INCYTE CORPORATION | 2019-07-11 | — | — | US | disclosed |
| US-10208002-B2 | Modulators of indoleamine 2,3-dioxygenase and methods of using the same | INCYTE CORPORATION (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180030006-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME | INCYTE CORPORATION | 2018-02-01 | — | — | US | disclosed |
| EP-3085697-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME | Incyte Holdings Corporation (US) | 2016-10-26 | — | — | EP | disclosed |
| US-20140377292-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME | INCYTE CORPORATION (US) | 2014-12-25 | — | — | US | disclosed |
| US-8846726-B2 | Modulators of indoleamine 2,3-dioxygenase and methods of using the same | INCYTE CORPORATION (US) | 2014-09-30 | — | — | US | disclosed |
| US-20130123246-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME | INCYTE CORPORATION (US) | 2013-05-16 | — | — | US | disclosed |
| EP-2559690-A1 | Modulators of indoleamine 2,3-dioxygenase and methods of using the same | Incyte Corporation (US) | 2013-02-20 | — | — | EP | disclosed |
| US-8372870-B2 | Modulators of indoleamine 2,3-dioxygenase and methods of using the same for treating cancer | INCYTE CORPORATION (US) | 2013-02-12 | — | — | US | disclosed |
| US-20110311479-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME | INCYTE CORPORATION, A DELAWARE CORPORATION | 2011-12-22 | — | — | US | disclosed |
| US-8034953-B2 | Modulators of indoleamine 2,3-dioxygenase and methods of using the same | INCYTE CORPORATION (US) | 2011-10-11 | — | — | US | disclosed |
| US-20060258719-A1 | Modulators of indoleamine 2,3-dioxygenase and methods of using the same | INCYTE CORPORATION | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10208002-B2 | Modulators of indoleamine 2,3-dioxygenase and methods of using the same | IDO1, IDO2, INMT | IDO1 1/4885POLB 3727/4885HPGD 72/4885 |
| US-20180030006-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME | IDO1, IDO2, INMT | IDO1 1/4885POLB 3727/4885HPGD 72/4885 |
| US-11192868-B2 | Modulators of indoleamine 2,3-dioxygenase and methods of using the same | IDO1, IDO2, INMT | IDO1 1/4885POLB 3727/4885HPGD 72/4885 |
| US-20060258719-A1 | Modulators of indoleamine 2,3-dioxygenase and methods of using the same | IDO1, IDO2, INMT | IDO1 1/4885POLB 3727/4885HPGD 72/4885 |
| US-20110311479-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME | IDO1, IDO2, INMT | IDO1 1/4885POLB 3727/4885HPGD 72/4885 |
| US-20190210985-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME | IDO1, IDO2, INMT | IDO1 1/4885POLB 3727/4885HPGD 72/4885 |
| US-20140377292-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME | IDO1, IDO2, INMT | IDO1 1/4885POLB 3727/4885HPGD 72/4885 |
| US-20130123246-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME | IDO1, IDO2, INMT | IDO1 1/4885POLB 3727/4885HPGD 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.